Melanocyte protein PMEL (gp100) - Heat shock protein 110 (Hsp110) complex (gp100-Hsp110)

The gp100 antigen via Hsp110 chaperone complex is a therapeutic immunogenic construct designed to treat melanoma by enhancing the immune system's recognition of tumor cells. gp100 (also known as PMEL) is a lineage-specific glycoprotein highly expressed in melanocytes and melanoma cells, serving as a key tumor-associated antigen [1]. Hsp110 (HSPH1) is a molecular chaperone that functions as a potent "chaperoadjuvant," capable of binding large protein antigens and facilitating their delivery to professional antigen-presenting cells like dendritic cells [2]. By complexing gp100 with Hsp110, the stability of the antigen is increased and its uptake is targeted through specific scavenger receptors, leading to enhanced cross-presentation of gp100 epitopes on MHC class I molecules [3]. This process is critical for breaking immunological tolerance and inducing a robust expansion of gp100-specific CD8+ cytotoxic T lymphocytes capable of lysing melanoma cells [4]. This vaccine strategy has been investigated in preclinical and early clinical settings to provide a more effective alternative to peptide-based vaccines for advanced melanoma [5]. Sources: [1] UniProt P40763 (PMEL_HUMAN). [2] UniProt Q92598 (HSPH1_HUMAN). [3] Wang, X. Y., et al. (2001). "Hsp110 and Grp170, efficiently bind proteins, deliver them to antigen-presenting cells, and elicit a potent anti-tumor immune response." Journal of Immunology. [4] Subjeck, J. R., et al. (2007). "Chaperone proteins as antigen-delivery systems." Expert Review of Vaccines. [5] Wang, X. Y., et al. (2004). "Characterization of hsp110 and grp170 as adjuvants and cancer vaccines." Methods.

Other names

gp100-Hsp110 vaccinePMEL-HSPH1 complexHsp110-gp100 chaperoadjuvant complexMelanoma-associated antigen gp100 - Heat shock protein 110 complexHsp110-gp100

The complex acts as a chaperoadjuvant where Hsp110 binds the gp100 antigen, facilitating its stable delivery to professional antigen-presenting cells (APCs) and promoting efficient cross-presentation of gp100 epitopes on MHC class I molecules to activate CD8+ cytotoxic T lymphocytes.